dry powder formulations
Recently Published Documents


TOTAL DOCUMENTS

62
(FIVE YEARS 4)

H-INDEX

20
(FIVE YEARS 0)

Pharmaceutics ◽  
2021 ◽  
Vol 13 (11) ◽  
pp. 1855
Author(s):  
Danforth P. Miller ◽  
Thomas E. Tarara ◽  
Jeffry G. Weers

Current dry powder formulations for inhalation deposit a large fraction of their emitted dose in the upper respiratory tract where they contribute to off-target adverse effects and variability in lung delivery. The purpose of the current study is to design a new formulation concept that more effectively targets inhaled dry powders to the large and small airways. The formulations are based on adhesive mixtures of drug nanoparticles and nanoleucine carrier particles prepared by spray drying of a co-suspension of leucine and drug particles from a nonsolvent. The physicochemical and aerosol properties of the resulting formulations are presented. The formulations achieve 93% lung delivery in the Alberta Idealized Throat model that is independent of inspiratory flow rate and relative humidity. Largely eliminating URT deposition with a particle size larger than solution pMDIs is expected to improve delivery to the large and small airways, while minimizing alveolar deposition and particle exhalation.


2021 ◽  
Vol 53 ◽  
pp. 101709
Author(s):  
Clarinda Costa ◽  
Beatriz Nobre ◽  
Ana Sofia Matos ◽  
Ana Sofia Silva ◽  
Teresa Casimiro ◽  
...  

Author(s):  
Danforth P. Miller ◽  
Thomas E. Tarara ◽  
Jeffry G. Weers

Current dry powder formulations for inhalation deposit a large fraction of their emitted dose in the upper respiratory tract where they contribute to off-target adverse effects and variability in lung delivery. The purpose of current study is to design a new formulation concept that more effectively targets inhaled dry powders to the large and small airways. The formulations are based on adhesive mixtures of drug nanoparticles and nanoleucine carrier particles prepared by spray drying of a co-suspension of leucine and drug particles from a nonsolvent. The physicochemical and aerosol properties of the resulting formulations are presented. The formulations achieve 93% lung delivery in the Alberta Idealized Throat model that is independent of inspiratory flow rate and relative humidity. Largely eliminating URT deposition with a particle size larger than solution pMDIs is expected to improve delivery to the large and small airways, while minimizing alveolar deposition and particle exhalation.


2021 ◽  
Vol 26 ◽  
Author(s):  
Qiuying Liao ◽  
K.W. Lam

: Pulmonary mycoses are associated with high morbidity and mortality. The current standard treatment by systemic administration is limited by inadequate local bioavailability and systemic toxic effects. Aerosolisation of antifungals is an attractive approach to overcome these problems, but no inhaled antifungal formulation is currently available for the treatment of pulmonary mycoses. Hence, the development of respirable antifungals formulations is of interest and in high demand. In this review, the recent advances in the development of antifungal formulations for pulmonary delivery are discussed, including both nebulised and dry powder formulations. Although the clinical practices of nebulised parenteral amphotericin B and voriconazole formulations (off-label use) are reported to show promising therapeutic effects with few adverse effects, there is no consensus about the dosage regimen (e.g. the dose, frequency, and whether they are used as single or combination therapy). To maximise the benefits of nebulised antifungal therapy, it is important to establish standardised protocol that clearly defines the dose and specifies the device and the administration conditions. Dry powder formulations of antifungal agents such as itraconazole and voriconazole with favourable physicochemical and aerosol properties are developed using various powder engineering technologies, but it is important to consider their suitability for use in patients with compromised lung functions. In addition, more biological studies on the therapeutic efficacy and pharmacokinetic profile are needed to demonstrate their clinical potential.


2020 ◽  
Vol 586 ◽  
pp. 119490 ◽  
Author(s):  
Sawittree Sahakijpijarn ◽  
Chaeho Moon ◽  
Xiangyu Ma ◽  
Yongchao Su ◽  
John J. Koleng ◽  
...  

Author(s):  
Tulshidas S. Patil ◽  
Ashwini Deshpande ◽  
Pravin K. Shende ◽  
Shirish Deshpande ◽  
Ram Gaud

ChemistryOpen ◽  
2018 ◽  
Vol 7 (10) ◽  
pp. 751-751
Author(s):  
Rita B. Restani ◽  
Rita F. Pires ◽  
Anna Tolmatcheva ◽  
Rita Cabral ◽  
Pedro V. Baptista ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document